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AbstrACt
Purpose The Jundiaí Zika Cohort (JZC) is a prospective 
pregnancy and birth cohort setup in the State of São 
Paulo, Brazil, to investigate the epidemic of cases of 
microcephaly and other neurological disorders, presumed 
to be associated with Zika virus (ZIKV) infection.
Participants A total of 748 women with high-risk 
pregnancies were recruited in the period of March 2016 to 
August 2017.
Findings to date Baseline sociodemographic and medical 
data were collected at recruitment from 737 pregnant 
women. Biological samples (ie, blood, saliva and urine) 
were collected from 695 of the pregnant women (94.3%), 
of whom 53 (7.6%) were ZIKV-positive on subsequent 
testing by reverse transcription polymerase chain reaction 
(RT-PCR) in urine. Biological sample (ie, blood, saliva, urine 
and cerebrospinal fluid) were collected within 10 days of 
birth from 409 (57.4%) of the liveborn infants, of whom 
19 (4.6%) were ZIKV-positive on subsequent testing by 
RT-PCR in urine. All remaining biological specimens, as 
well as colostrum, umbilical cord and placental samples, 
have been stored in a secure biorepository. Antenatal and 
postnatal imaging studies and neonatal anthropometry 
were carried out.
Future plans The JZC provides a unique data set 
which will continue to be explored to study the effects of 
pregnancy comorbidities on Zika virus infection during 
pregnancy, the long-term outcomes of children with 
congenital Zika infection and how physiotherapy and group 
interventions can improve outcomes for congenitally-
infected children. All women in the cohort have reached 
the end of their pregnancy and currently the oldest 
children are 2 years old. The study will continue until all the 
children reach their third birthday (April 2021).
IntroduCtIon
The Jundiaí Zika Cohort (JZC) is an ongoing 
multidisciplinary longitudinal study which is 
following a cohort of pregnant women and 
their children to study the effects of prenatal 
Zika virus (ZIKV) exposure. The cohort was 
set-up in response to the clusters of cases of 
severe microcephaly and associated neuro-
logical disorders that were reported in areas 
affected by ZIKV in the Northeast of Brazil in 
October 20151 and that provoked the Public 
Health Emergency of International Concern 
declared by the WHO on 1st February 
2016.2 At this point in time, the São Paulo 
Research Foundation (FAPESP) encouraged 
all researchers who had been part of the 
Brazilian Genome Project to submit thematic 
research project proposals addressing the 
potential causes of the cluster of cases of 
microcephaly.
Laboratory confirmation of autochthonous 
ZIKV transmission in Brazil was first estab-
lished in the north-eastern states of Pernam-
buco, Rio Grande do Norte and Bahia, and 
later in other states of the central-west and 
south-eastern regions of Brazil. When the JZC 
was set-up, there was no published data about 
the ZIKV epidemic in São Paulo state. It was 
not known how the differences in climate 
and socioeconomic status between this south-
eastern state and the poorer and more trop-
ical north-eastern regions, where the ZIKV 
epicentre was focused, would influence the 
strengths and limitations of this study
 ► The Jundiaí Zika Cohort (JZC) is one of the few pro-
spective Zika cohort studies that has recruited both 
asymptomatic and symptomatic pregnant women 
and therefore benefits from having a large control 
group.
 ► The high-risk profile of the pregnant women pro-
vides a unique opportunity to study comorbidities 
that may contribute to, or potentially be protective 
for, the development of negative sequelae associat-
ed with Zika virus (ZIKV) exposure.
 ► The prevalence of ZIKV reverse transcription poly-
merase chain reaction positivity was relatively low 
in this study population resulting in small numbers 
for estimating absolute and relative risks.
 ► Because high-risk pregnant women are at higher 
risk of developing some of the outcomes of interest, 
this may have reduced the power to detect differ-
ences between Zika-exposed and unexposed dyads.
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epidemic. The study site of Jundiaí in the south-eastern 
state of São Paulo was therefore chosen in order to 
explore these variations.
This cohort profile aims to describe the Jundiaí Zika 
Cohort including: The context behind its creation, 
materials and methodology, recruitment and follow-up 
of pregnant women and children as well as some of its 
preliminary results. The oldest children of the cohort, as 
of November 2018, are 2 years old; all the children will be 
followed up until their third birthday.
Cohort desCrIPtIon
study site
The JZC is housed in the paediatric department of the 
Jundiaí Medical School in the city of Jundiaí, São Paulo 
state. Jundiaí is 50 km northwest of the city of São Paulo 
(figure 1) and has a population of 405 740 inhabitants.3 It 
has a relatively high Human Development Index ranking 
11th out of the total 5565 municipalities in the country.3 
The climate in the area is humid subtropical, according 
to the Köppen classification, with a mean annual 
temperature of 20.9°C. The majority (64%) of the land 
in the municipality of Jundiaí is considered rural and 
31% of this is made up of the Japi Mountain, a Biosphere 
Reserve of Atlantic Forest recognised by UNESCO since 
1994.4 Jundiaí University Hospital is the only public 
maternity facility in the municipality of Jundiaí and is the 
local referral centre for high-risk pregnancies. In 2017, 
37.6% of babies born in the municipality were born in 
this hospital; the remaining 62.4% were born in one of 
three private hospitals in Jundiaí.5
Given the severity of the phenotype assumed to be asso-
ciated with prenatal exposure to ZIKV and the urgent 
need to establish a cause, the JZC, like many other 
Zika Cohorts in Brazil, commenced without any formal 
funding on 1st March 2016. It later received seed funding 
from The London School of Hygiene and Tropical Medi-
cine prior to obtaining formal FAPESP funding for a 
thematic research project over a year after the initiation 
of the project on 1st April 2017 (figure 2).
Figure 1 Map showing the location of the municipality of 
Jundiaí in the State of São Paulo, Brazil.19 CSF, cerebrospinal 
fluid; PCR, polymerase chain reaction; USS, ultrasound scan; 
ZIKV, Zika virus. 
Figure 2 The context of the initiation of the Jundiaí Zika Cohort presented as a timeline of events related to the introduction of 
ZIKV in Brazil in the period 2015 to 2017 and beyond.2 20–23 ZIKV, Zika virus. 
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Following ethical approval for the study from the 
research ethics committee of Jundiaí Medical School 
(protocol number 1446577), written informed consent 
was obtained from participating women for themselves 
and for future follow-up of their child.
This cohort profile describes the recruitment and 
follow-up of the pregnant women and children in the 
JZC. The oldest children of the cohort, as of November 
2018, are 2 years old; all the children will be followed up 
until their third birthday.
Cohort desCrIPtIon
eligibility and recruitment
All pregnant women attending the high-risk pregnancy 
clinic at Jundiaí University Hospital (referred from one 
of the 38 basic health units in the Jundiaí area due to 
the presence of risk factors that could affect the well-
being of themselves or their unborn child)6 between 1st 
March 2016 and 23rd August 2017 were invited to partic-
ipate. Common risk factors included diabetes, hyper-
tension, twin pregnancy and adolescent pregnancy. The 
only exclusion criteria at this stage were women who had 
life-threatening conditions and women who had severe 
learning difficulties. The reasons for choosing this study 
population of high-risk pregnant women were (i) to try to 
maximise recruitment efficiency and pregnancy follow-up 
adherence, (ii) to provide an appropriate location for 
the examination of the women and collection of clin-
ical samples and (iii) to optimise newborn data quality 
by ensuring a large proportion would be born in Jundiaí 
University Hospital. Over the duration of follow-up, clin-
ical teams cared for pregnant women in accordance with 
the Brazilian Ministry of Health protocols.
As the study commenced in the midst of the ZIKV 
outbreak in Brazil, and seroprevalence studies had not 
been carried out, it was not known what the true incidence 
or prevalence of ZIKV infection was in the Jundiaí area; or 
indeed what the prevalence of microcephaly was in either 
ZIKV exposed or unexposed pregnant women. In 2016, 
in the State of São Paulo, 9845 cases of ZIKV infection 
were reported to the Brazilian Notifiable Disease Registry 
(SINAN) of which 5056 were considered probable, giving 
a crude incidence of 11.3 cases of ZIKV per 100 000 
inhabitants in the State of São Paulo in the year 2016.7 
However, this is likely to be a gross underestimation.
The sample size for the cohort was calculated using an 
estimated prevalence of cases of microcephaly among 
neonates of ZIKV reverse transcription polymerase chain 
reaction (RT-PCR) positive pregnant women of 2%. A 
final analytical cohort size of n=531 would give us 80% 
power to detect a crude relative risk of 2 with a proba-
bility of type I error (α) of 5%.8 Although initially the 
JZC aimed to enrol 500 pregnant women, recruitment 
continued for longer than initially anticipated to try to 
capture possible seasonal differences in the incidence of 
ZIKV disease.
study participant characteristics
During the recruitment period, 752 women were enrolled 
in the study (figure 3). Of these, 15 (2%) were excluded 
as the baseline questionnaire was not fully administered. 
The mean age of women was 27.5 years (13 to 46). Three 
hundred and sixty-eight (53.7%) of the women were 
of white ethnicity, 238 (34.7%) mixed race or brown 
(known as ‘parda’ in Portuguese), 66 (9.6%) black, 11 
(1.6%) Asian and 2 (0.3%) indigenous. Five hundred and 
sixty-nine (77.2%) of the women reported being married 
or living with their partner (table 1). During pregnancy, 
231 (33.9%) of the women had diabetes and 129 (18.9%) 
had hypertension. The presence of other risk factors, or 
comorbidities, is detailed in table 2.
Of the 737 pregnant women with full baseline informa-
tion collected, 695 (94.3%) provided biological samples 
(ie, blood, saliva and urine from each) for ZIKV testing. 
Of the 695 women whose urine was tested by RT-PCR, 53 
(7.6%) were ZIKV-positive. Due to financial constraints 
during the outbreak, blood and saliva collected from 
both women and neonates have been stored in a biore-
pository for future testing. Twenty-six (3.4%) women 
were lost to follow-up during pregnancy (ie, before 
the birth outcome), and there was one first trimester 
maternal death. Of the 710 women who were followed 
until the birth outcome, 23 (3.2%) had foetal losses and 
687 (96.9%) had live births, of which 25 (3.6%) were twin 
pregnancies.
Of the 712 live births, 376 (52.7%) were female (table 3). 
Of these, 655 (92.0%) had anthropometry at birth (a 
minimum of weight and head circumference measured 
at birth); the mean birth weight among live births was 
3001 g (590 g to 4525 g), mean length at birth was 47.5 cm 
(28.5 cm to 58.5 cm) and mean head circumference was 
33.7 cm (22 cm to 38.5 cm). The number of liveborn 
infants who had urine tested for ZIKV RT-PCR within 10 
days of birth was 409 (57.4%). Of these, 19 (4.6%) were 
positive. Notably, no neonates presented with symptoms 
consistent with postnatal ZIKV infection in the first 10 
days. Of the 712 live births, 271 (38.1%) babies were seen 
in the JZC paediatric clinic between 0 to 2 months of age, 
186 (26.1%) between 3 to 4 months of age, 173 (24.3%) 
between 5 to 6 months of age, 218 (30.6%) between 
7 to 12 months of age and 74 (10.4%) between 13 to 24 
months of age. So far, no infants have been followed up 
beyond 2 years of age.
external validity and possible participation biases
The recruitment of only high-risk pregnant women 
brought advantages, as discussed earlier, in both logis-
tics and maximisation of follow-up rates, however, these 
advantages also introduced limitations in external 
validity when generalising JZC findings to the general 
pregnant population of Brazil. Moreover, as recruitment 
was carried out in a specific population of pregnant 
women that were users of a particular health service, it 
is possible that there are systematic differences between 
those recruited and those not recruited, which we were 
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not able to measure, and these may have introduced 
bias. However, when comparing the sociodemographic 
profile of the pregnant women in our cohort and the 
profile of pregnant women living and using public 
maternity facilities in the State of São Paulo at the time 
of the study,9 10 we can see that they are quite similar. For 
example, around half of the women were white, around 
half had vaginal deliveries and the majority had finished 
Figure 3 Flow diagram showing participants of the Jundiaí Zika Cohort at each stage of the study, recruitment period: 01 
March 2016 to 23 August 2017, Jundiaí, São Paulo, Brazil.
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high school and were co-habiting and/or married to 
their partner (table 1).
Furthermore, as there is no known association between 
high-risk pregnancies and  congenital Zika syndrome 
(CZS), we do not anticipate that the restricted selection 
criteria of the cohort would have a significant impact on 
our interpretation of the underlying biology of congen-
ital ZIKV infections.
Follow-uP
Pregnant women
Women who at enrolment reported not having had any 
symptoms consistent with ZIKV infection during their 
pregnancy (and who were currently asymptomatic), 
according to the WHO ZIKV clinical case definition,11 
were followed up as per Group 1 and women who were 
symptomatic at any point during pregnancy were followed 
up as per Group 2 (figure 3). Women were asked to 
contact the research team and attend the hospital if they 
experienced any symptoms consistent with ZIKV infection 
at any point in their pregnancy so that biological samples 
could be collected as detailed below. In addition, trained 
volunteers carried out weekly telephone follow-up consul-
tations at pre-arranged times that were convenient for the 
women until the time of birth to ask specifically about 
the occurrence of any ZIKV symptoms and any women 
who had experienced symptoms were advised to go to the 
hospital.
Regardless of symptom occurrence, women in both 
groups were seen 14 to 21 days after enrolment for 
biological sample collection and then in 2 to 3 monthly 
intervals thereafter (sample collection details and labo-
ratory procedures are described below). Antenatal ultra-
sound scanning was carried out in months 3, 5, 7 and 
8 in asymptomatic (Group 1) women and monthly in 
symptomatic (Group 2) women at the São Paulo foetal 
medicine centre (CPMF). Additionally, where malforma-
tions, signs of congenital ZIKV infection or intra-uterine 
growth restriction were found, ultrasound scanning was 
carried out weekly at Jundiaí University Hospital or CPMF 
(figure 4).
neonates, infants, children
Women whose birth outcomes resulted in a live birth were 
invited to come to the JZC paediatric follow-up clinic 
Table 1 Description of women in the Jundiaí Zika cohort
Pregnant women (n=737)
Age in years (mean and 
range)
27.5 (13–46)
  Ethnicity White 53.7 % (n = 368) 
  Mixed race 34.7 % (n = 238) 
  Black 9.6 % (n = 66) 
  Asian 1.6 % (n = 11) 
  Indigenous 0.3 % (n = 2) 
  Unknown 7.1% (n=52)
Education >12 years 15.4% (n=106)
  12 years 44.4 % (n = 305) 
  9–11 years 23.7 % (n = 163) 
  ≤8 years 16.4 % (n = 113) 
  Unknown 6.8 % (n = 50) 
Married/living with partner 77.2% (n=569)
Biological sample tested 
for ZIKV RT-PCR during 
pregnancy
94.3% (n=695)
Positive maternal urine ZIKV 
RT-PCR during pregnancy
7.6% (n=53)
Lost to follow-up before birth 
outcome
3.5% (n=26)
Maternal deaths 0.1% (n=1)
Women with live births (of 
those followed up)
97.6% (n=687)
Foetal deaths 3.2% (n=23)
*Note: Percentages for all categories were calculated with 
exclusion of those with missing data from the denominator.
RT-PCR, reverse transcription polymerase chain reaction; ZIKV, 
Zika virus. 
Table 2 Presence of risk factors (comorbidities) among 
pregnant women in the Jundiaí Zika cohort
Risk factor
Proportion (n) of women 
with risk factor (total 
n=682)
Diabetes 33.9% (231)
Hypertension 18.9% (129)
Adolescent 10.0% (68)
Urinary tract infection 5.6% (38)
Twin pregnancy 4.3% (29)
Hypothyroidism 4.1% (28)
Obesity or previous bariatric 
surgery
3.2% (22)
Pre-eclampsia 2.6% (18)
Syphilis 2.3% (16)
Asthma 2.1% (14)
Previous preterm labour or foetal 
death
1.8% (12)
Epilepsy 1.8% (12)
Threatened preterm labour 1.6% (11)
Heart disease 1.5% (10)
Anaemia (including sickle cell 
and thalassaemia)
1.3% (9)
Illicit drug use 1.0% (7)
Psychiatric illness 0.7% (5)
HIV 0.4% (3)
Note: Categories are not mutually exclusive.
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within the neonate’s first month of life. Subsequently, 
mothers were asked to bring their children back monthly 
in the first 12 months of life and at 3 monthly intervals 
thereafter until they completed 36 months.
At each stage of follow-up there was a significant 
non-response rate (see figure 3). Pregnant women 
and mothers who did not attend a scheduled follow-up 
appointment were contacted by phone, mobile or Face-
book. In addition, JZC teams visited and spoke to staff at 
the basic health units in Jundiaí and requested them to 
refer on any children belonging to the cohort. Despite 
these efforts, for many families, a complex and precarious 
social situation precluded them from being able to attend 
the follow-up appointments.
dAtA ColleCtIon
The JZC is a multidisciplinary study containing a rich 
range of information regarding the follow-up and 
outcomes of the JZC mothers and children, both exposed 
and unexposed to ZIKV during pregnancy. The main 
health, medical and laboratory data collected to date are 
listed in table 4.
The initial baseline questionnaire administered to the 
pregnant women was designed by the JZC researchers 
before any internationally standardised collection tool 
had been developed. In August 2016, the WHO created 
a standardised questionnaire in order to streamline data 
collected by all the Zika cohorts12; new questions which 
were not already in the initial JZC tool (mainly related 
to environmental exposures, for example mosquito repel-
lent and bednet use, type of housing and water sources) 
were added.
Four specialist foetal medicine doctors carried out the 
antenatal ultrasound scans at the CPMF with Voluson 
S10, Voluson E6 e Voluson E8 GE Healthcare equipment. 
Table 3 Description of liveborn infants in the Jundiaí Zika 
cohort
Liveborn infants (n=712)
Twin pairs 3.5% (n=25)
Sex (female) 52.8% (n=376)
Delivery method 
  Vaginal 47.1 % (n = 330) 
  Caesarean section 50.3 % (n = 352)
  Forceps 2.6 % (n = 18)
  Unknown 1.7 % (n = 13)
  Weight at birth in grams (mean 
and range) 
3001 (590 – 4525) 
Length at birth in cm (mean and 
range)
47.5 (28.5–58.5)
Head circumference at birth (mean 
and range)
33.7 (22–38.5)
Biological sample tested for ZIKV 
RT-PCR at<10 days
57.4% (n=409)
Positive urine ZIKV RT-PCR in first 
10 days of life
4.6% (n=19)
Note: Percentages for all categories were calculated with exclusion 
of those with missing data from the denominator.
RT-PCR, reverse transcription polymerase chain reaction; ZIKV, 
Zika virus. 
Figure 4 Full follow-up protocol for Jundiaí Zika cohort study (01 March 2016 to  23 August 2017), Jundiaí, São Paulo, 
Brazil. JZC, Jundiaí Zika Cohort; ZIKV, Zika virus. 
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Foetal anthropometry was carried out and gestational age 
estimated.
Anthropometry was carried out in neonates in the 
first hour of life unless their condition was unstable. 
Head circumference was measured using a non-elastic 
tape measure placed between forehead and occiput, 
weight was measured using digital scales and length 
using a recumbent baby length scale. Z-scores for these 
measurements were then calculated using the INTER-
GROWTH-21st curves13–15 which take into account the sex 
and gestational age of the neonate. Gestational age was 
calculated using first-trimester ultrasound when available 
and last menstrual period when not available.
Clinical samples and laboratory procedures
Blood, saliva and urine were collected from the women 
and children by nursing staff, healthcare assistants and 
auxiliary nurses (all registered at the nursing professional 
registration body of the State of São Paulo (COREN-SP)) 
following an in-house standardised protocol. Personal 
protective measures were taken (gloves and eye protection 
were worn at all times) and samples were labelled appro-
priately with the patient name, date of collection, date of 
birth and sample number). Saliva samples were collected 
by swabbing 10 times on the inside of each cheek with 
sterile swabs which were then placed into sterile Falcon 
15 mL tubes. Women were asked to provide urine samples 
into 50 mL sterilised collection tubes. For neonatal and 
infant urine samples, sterile urine collecting bags with 
adhesive tape were placed over sterilised skin around the 
penis/vulva. At birth, blood was collected from the umbil-
ical cord and subsequently, in infants and women, blood 
samples were obtained by venepuncture in the antecu-
bital fossa or in the dorsum of the hand with a maximum 
of three attempts. Blood was collected into dry and EDTA 
Table 4 The Jundiaí Zika cohort, summary of health, medical and laboratory data collected from women and their children
Phase Measurements
Pregnant women at 
enrolment
Baseline questionnaire - sociodemographic details, past medical history, family history, past obstetric history 
(parity, miscarriages, mode of delivery, malformations), current obstetric history (if pregnancy was planned, 
use of tobacco, alcohol, drug and medications and vaccinations received), presence of symptoms/signs 
consistent with ZIKV infection (fever, rash, non-purulent conjunctivitis, arthritis/arthralgia, lymphadenopathy, 
myalgia, headache) at any point throughout pregnancy, the woman’s environment (type of housing, number 
of rooms, number of people per household), preventative measures (use of repellent, protective clothing, 
window or bed nets, barrier contraception) and their knowledge of ZIKV and its forms of transmission as 
well as what their sources of information were
Pregnant women follow-
up 14–21 days after 
enrolment
Sample collection (blood, saliva, urine) for ZIKV RT-PCR and IgG/IgM
Symptoms questionnaire - presence of symptoms/signs consistent with ZIKV infection (timing, duration, 
intensity, action taken)
Pregnant women 
subsequent 2–3 monthly 
follow-ups
Sample collection (blood, saliva, urine) for ZIKV RT-PCR and IgG/IgM
Symptoms questionnaire - presence of symptoms/signs consistent with ZIKV infection (timing, duration, 
intensity, action taken)
Antenatal ultrasound at São Paulo foetal medicine centre
Pregnant women weekly 
phone follow-up
Symptoms questionnaire - presence of symptoms/signs consistent with ZIKV infection (timing, duration, 
intensity, action taken)
Birth (mother and 
neonate)
Sample collection (blood, saliva, urine) for ZIKV RT-PCR and IgG/IgM. Colostrum (mother) and cerebrospinal 
fluid (neonate exposed to ZIKV and/or with microcephaly) for ZIKV PCR.
Anthropometry – weight, length, head circumference (neonate)
Placenta and umbilical collection - pathology
Neonatal, infant and 
child follow-ups
Sample collection (blood, saliva, urine) for ZIKV RT-PCR and IgG/IgM in months 1, 3, 6 and 15 for neonates. 
(Women found to be ZIKV RT-PCR positive during pregnancy also had blood, saliva and urine collected 
during paediatric follow-up appointments).
Paediatric follow-up questionnaire – problems, significant events, feeding, vaccinations, developmental 
milestones reached, review of lab test results (including heel-prick test)
Anthropometry – weight, length, head circumference
Paediatric physical examination – general, cardiovascular, respiratory, gastrointestinal, neurological, 
developmental
Physiotherapy assessment
Speech and language assessment
ZIKV exposed 
infants and/or with 
microcephaly/
other neurological 
abnormalities
Opthalmology assessment (with Teller-CAT Cambridge Colour Test, funduscopy and extrinsic ocular motility 
tests)
Specialist neurodevelopmental assessment (using Bayley-III developmental scales)
Specialist audiology assessment
Gastrointestinal assessment
Imaging – Cranial ultrasound and CT brain at birth and 12 months
PCR, polymerase chain reaction; RT-PCR, reverse transcription polymerase chain reaction; ZIKV, Zika virus. 
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tubes which were mixed and labelled appropriately and 
placed in the fridge.
ELISA for identification of anti-ZIKV immunoglobulins (IgM and IgG)
Detection of anti-ZIKV antibodies (IgM and IgG) was 
performed by ELISA using commercial Zika IgG and 
Zika IgM ELISA kits Euroimmun (Euroimmun BR 2015), 
approved by the National Sanitary Surveillance Agency 
(ANVISA) for the diagnosis of ZIKV.
Serum, blood or plasma were diluted 1:101 in sample 
buffer. For IgM detection, the buffer contains an IgG/
RF absorbent (preparation of anti-goat IgG). After, 
100 µL of this dilution was applied to each well of the 
plates. The plates were covered with protective film and 
incubated for 60 min at +37°C. After the first incuba-
tion, the plates were washed with 400 µl of wash buffer 
(1X). One hundred microliters of the enzyme conjugate 
(peroxidase-labelled human IgG and IgM) were applied 
to each well, followed by incubation for 30 min at room 
temperature. Another wash was performed, under the 
same conditions described previously. In each well 100 µL 
of the substrate/chromogen was added, followed by 
incubation for 30 min at room temperature, protected 
from light. After washing, 100 µL of Stop solution was 
added and the plates were read in Automatic Biochem-
ical Analyzer, model prietest TOUCH (2009 ROBONIK 
India), in 450 mn absorbance.
For the detection of IgG, three calibrators were used 
plus the negative and positive controls contained in the 
kit. For IgM detection a calibrator plus the positive and 
negative controls were used. The cut-off was calculated by 
the ratio between the absorbance of the controls and that 
of the calibrators. Samples with a cut-off <0.8 and positive 
samples with a cut-off of ≥1.1 were considered negative. 
The samples with a cut-off between ≥0.8 and 1.1 were 
considered equivocal.
Real time PCR for ZIKV detection
ZIKV RNA detection was performed by real time PCR 
(RT-qPCR), as recommended by the WHO, according to 
the protocol developed by Lanciotti et al16 on maternal 
and neonatal urine samples.
Initially, the total RNA was extracted from 140 µL of 
urine using the QIAamp Viral RNA Mini Kit (QIAGEN), 
following manufacturer's instructions. The final RNA was 
eluted in 60 µl of ultrapure H2O Nuclease-Free Water 
(2018 Merck KGaA, Darmstadt, Germany) and RT-qPCR 
was performed on the same day. The remaining RNA 
was stored in a freezer at −80°C. RT-qPCR was performed 
with GoTaq Probe qPCR and RT-qPCR Systems (2018 
Promega Corporation Brasil, Ltda). For the final volume 
of 20 µl reaction, 8 µl of RNA template was used. The Mix 
was created with 10 µl of GoTaq Probe qPCR Master Mix 
with dUTP (1x), 0,4 µl of GoScript RT Mix for 1-Step 
RT-qPCR (1x), 1 µl of Forward primer (10 pmol/µL), 1 µl 
of Reverse primer (10 pmol/µL), 1 µl of probe (10 pmol/
µL) (table 5) and of Nuclease-Free Water to complete the 
final volume. Two sets of primers and probe were used 
on the RT-qPCR reaction. The reaction occurred in ABI 
Prism 7500 SDS Real-Time cycler (Applied Biosystems), 
where the amplification cycles consisted of: One cycle 
of 15 min at 45°C for reverse transcription, one cycle of 
2 min at 95°C for reverse transcriptase inactivation and 
for polymerase activation, 40 cycles of 15 s at 95°C for 
denaturation and 1 min at 60°C for annealing and exten-
sion. The primers and probes used for this quantification 
are complementary to the gene encoding the NSI protein 
of ZIKV (table 5). The probe contains a fluorescent 
6-carboxyfluorescein (FAM) reporter dye at the 5’ end 
and the fluorescent dye 6-carboxytemethylhydhodamine 
(TAMRA) at the 3’ end. All reactions followed positive 
and negative controls previously quantified.
The placenta and umbilical cord were collected and 
stored in formaldehyde and sent to the pathology labo-
ratory where they were examined by specialist placental 
pathologists.
Patient and public involvement
As can be seen in the timeline of the creation of the JZC 
(figure 2), the wider community were invited to partici-
pate in the design of the JZC study and to join the research 
team to be trained as volunteers. Some of these members 
of the public were then involved with recruitment to the 
study and responsible for the dissemination of informa-
tion about the study to their local communities. As the 
JZC involves a long follow-up period of pregnant women 
and their children, personal clinical results have been 
Table 5 Primer and probe sets used for RT-qPCR ZIKV detection
Primer/probe set Primer and/or probe Genome position Sequence (5’ – 3’)
Set 1 ZIKV 835 835–857 TTGGTCATGATACTGCTGATTGC
ZIKV 860-FAM 860–886 CGGCATACAGCATCAGGTGCATAGGAG
ZIKV 911 c 911–890 CCTTCCACAAAGTCCCTATTGC
Set 2 ZIKV 1086 1086–1102 CCGCTGCCCAACACAAG
ZIKV 1107-FAM 1162–1139 AGCCTACCTTGACAAGCAGTCAGACACTCAA
ZIKV 1162 c 1107–1137 CCACTAACGTTCTTTTGCAGACAT
Primers designed by Lanciotti et al, 2008 (Based on ZIKV MR 766 GenBank accession no. AY632535).
FAM, fluorescent 6-carboxyfluorescein; PCR, polymerase chain reaction; RT-qPCR, real time quantitative PCR; ZIKV, Zika virus. 
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regularly communicated to patients and their families. In 
addition, any relevant study findings have also been care-
fully and appropriately explained.
Findings to date
ZIKV clinical features during pregnancy
The clinical features of ZIKV infection among pregnant 
women in the JZC have been described. They have been 
used to assess the sensitivity of the current standard clin-
ical case definitions, and to investigate whether adverse 
foetal outcomes are more likely to occur among pregnant 
women with symptomatic ZIKV infection during preg-
nancy compared with asymptomatic infection.
Foetal outcomes after congenital ZIKV exposure
This includes studies comparing the incidence of negative 
foetal outcomes, namely low birth weight, small-for-gesta-
tional age, prematurity and foetal death among ZIKV-ex-
posed and unexposed women. Studies have also looked at 
the prevalence of Chikungunya IgG among mothers who 
had foetal losses.
Congenital Zika syndrome
The spectrum of congenital Zika virus syndrome in the 
JZC children has been explored as well as visual acuity 
alterations among ZIKV exposed babies, including among 
dizygotic twins.
The placenta
Placental histological findings among ZIKV exposed 
infants with microcephaly have been reported as well 
as placental histological findings among mothers with 
Chikungunya and Dengue infection.
Environmental risk factors, prevention, educational and vector 
control activities
These studies have included investigations into the envi-
ronmental risk factors for ZIKV infection, assessment of 
the peri-domicile environment of women in the JZC and 
identification of favourable conditions for replication 
evaluation of educational activities for children to help 
combat the proliferation of Aedes aegypti and assessment 
of the knowledge around the modes of transmission and 
prevention of ZIKV infection as well as the practice of 
preventative measures among pregnant women in the 
cohort.
Susceptibility of ZIKV infection of neural progenitor cells among 
dizygotic twins
Analysis of neural progenitor cells (NPCs) of dizygotic 
twins discordant for CZS have shown that the develop-
ment of CZS depends on the intrinsic susceptibility of the 
NPCs.17
Seroepidemiological arbovirus studies
Studies quantifying the seroprevalence of ZIKV, Chiku-
ngunya and Dengue IgG antibodies among pregnant 
women in the JZC have been carried out.
Of note, unless referenced, these manuscripts are 
awaiting final publication.
strengths and limitations
The JZC is one of the few prospective Zika cohort studies 
that has recruited both asymptomatic and symptomatic 
women and therefore benefits from having a large control 
group. It also provides the necessary study population 
to carry out analyses on ZIKV symptomatology. Women 
were recruited over more than a 1 year period of time 
(March 2016 to August 2017) and therefore seasonality 
can be explored. The diversity and frequency of biolog-
ical samples collected from the women during pregnancy 
(and after), as well as their children, mean that JZC now 
has a rich and invaluable biorepository of clinical mate-
rial. The high-risk profile of the pregnant women also 
provides an additional unique opportunity to study other 
factors that may contribute to, or potentially be protec-
tive for, the development of negative sequelae associated 
with ZIKV exposure. The JZC implemented the use of 
standardised WHO research method tools, as soon as 
they were available, and therefore has placed itself in an 
optimal position to collaborate in Brazilian and interna-
tional consortia that will ultimately be aiming to perform 
meta-analyses on all Zika cohort study data.
The limitations of the JZC in part relate to the pressing 
nature of the ZIKV and microcephaly epidemic and the 
urgency to start the investigation. The JZC, like many other 
Zika studies, commenced without any formal funding. 
Recruitment and data collection commenced in paper 
form, before formal data management systems could be 
put in place. In addition, as WHO standardised research 
protocols were produced after the start of the investiga-
tion, some variables contained in the WHO protocol were 
not in our original questionnaire and therefore some of 
this data is missing for the earliest recruits in our cohort. 
As this cohort was built in the midst of the ZIKV epidemic 
with limited financial resources, the scientific leadership 
team opted to prioritise the testing of urine samples by 
RT-PCR due to its wider window of detection (eg, up 
to 2 weeks in urine vs 1 week in serum).16 18 Although 
important tests (eg, IgG and IgM assays and plaque reduc-
tion neutralization test  (PRNT)) and the infrastructure 
required to perform them have continued to be too costly 
for testing using available resources, the relevant serum 
samples have been stored in a secure biorepository for 
future evaluation on procurement of additional funding. 
An additional limitation related to testing is the possibility 
of misclassification among a minority of the ZIKV-positive 
newborns who may have been infected postnatally during 
the first 10 days of life. The choice of study population 
(high-risk pregnant women) had several advantages 
as stated above. However, there are also a few draw-
backs that should be highlighted. First, because women 
were not recruited based on a suspicion of having been 
exposed to ZIKV, the prevalence of ZIKV RT-PCR posi-
tivity was relatively low, and this equated to small numbers 
for estimating absolute and relative risks. Furthermore, 
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because high-risk pregnant women are at higher risk of 
developing some of the outcomes of interest, this may 
have reduced the power for us to detect differences in 
frequency of outcomes between Zika-exposed and unex-
posed dyads. The differential follow-up of women who 
were symptomatic for ZIKV infection in terms of a more 
intensive antenatal scanning schedule prioritised women 
with clinical ZIKV infection (consistent with the WHO 
definition)11 to try to improve our understanding of the 
sequence of events that occur in utero after ZIKV infec-
tion. As we were unable to offer monthly ultrasounds to 
all the women in the cohort, this differential follow-up 
may have also had consequences in terms of the detec-
tion of problems in the antenatal period. With regards to 
the neonatal outcomes, the loss to follow-up that we inev-
itably experienced may also reduce the power for us to 
detect differences in the frequency of outcomes between 
Zika-exposed and unexposed neonates.
CollAborAtIon
The JZC headquarters is at the Jundiaí Medical School 
under the direction of Professor Saulo Duarte Passos. 
The cohort has a Facebook page: https://www. facebook. 
com/ zikacoortejdi/ which contains information about 
the functioning and organisation of the JZC, fundraising 
events, support for Zika affected families and media 
coverage. Any researcher wanting to use JZC data must 
apply to the Jundiaí Zika Cohort Group via Professor 
Passos ( sauloduarte@ uol. com. br).
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